India, Nov. 3 -- China Medical System Holdings Ltd. (0867.HK) said its subsidiary, Rxilient Medical, received approval from Singapore's Health Sciences Authority (HSA) on Tuesday, November 3, for Lumirix (ruxolitinib phosphate cream).
The cream is approved to treat non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older.
The company said Lumirix is the first and only topical prescription drug in Singapore that directly targets the underlying disease process in vitiligo.
The chronic autoimmune disease causes patches of skin to lose colour as pigment-producing cells are lost. China Medical System estimates that vitiligo affects about 0.7% of Singapore's population.
Developed by Incyte Corp., Lumirix crea...